133 results match your criteria: "Dana Faber Cancer Institute[Affiliation]"
Cancer Biol Ther
September 2006
Dana Faber Cancer Institute, Boston, Massachusetts 02115, USA.
Oncologist
February 2006
Dana-Faber Cancer Institute/Harvard Medical School, Boston, MA, USA.
Background: Substantial debate centers on the high cost and relative value of new cancer therapies. Oncologists play a pivotal role in treatment decisions, yet it is unclear whether they perceive high-cost new treatments to offer good value or how therapeutic costs factor into their treatment recommendations.
Methods: We surveyed 139 academic medical oncologists at two academic hospitals in Boston.
J Clin Oncol
September 2005
Brigham and Women's Hospital, Dana-Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Purpose: For men receiving androgen-suppression therapy (AST) for a rising postoperative or postradiation prostate-specific antigen (PSA), we evaluated whether a PSA nadir of more than 0.2 ng/mL was significantly associated with prostate cancer-specific mortality (PCSM).
Patients And Methods: The study cohort comprised 747 men with rising PSA and negative bone scan after surgery (n = 486) or radiation therapy (n = 261) who were treated with AST.
J Clin Oncol
August 2005
Brigham and Women's Hospital, Department of Radiation Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Purpose: We evaluated whether men at risk for significant versus clinically insignificant prostate-specific antigen (PSA) failure after radical prostatectomy could be identified using information available at diagnosis.
Patients And Methods: A prospective prostate cancer screening study that enrolled, diagnosed, and treated 1,011 men with radical prostatectomy at Barnes-Jewish Hospital (St Louis, MO) from January 1, 1989, to June 1, 2002, for localized prostate cancer formed the study cohort. Preoperative predictors of a postoperative PSA doubling time (DT) of less than 3 months and more than 12 months or no PSA failure were identified using logistic regression.
Clin Prostate Cancer
June 2005
Department of Medical Oncology, Lake Center for Genitourinary Oncology, Dana-Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Few treatment options are available for patients with metastatic hormone-refractory prostate cancer (HRPC) that is not responsive to or continues to progress after taxane-based chemotherapy. Although single-agent carboplatin has modest activity in HRPC, carboplatin chemotherapy could induce a synergistic effect when combined with taxanes in patients with disease resistant to taxane-based chemotherapy. We report a case series of 4 consecutive patients treated with docetaxel (60-70 mg/m2) plus carboplatin (area under the curve of 4/5) following progression after taxane-based chemotherapy.
View Article and Find Full Text PDFStat Methods Med Res
December 2004
Dana-Faber Cancer Institute, Department of Biostatistics and Computational Biology, 44 Binney Street, Boston, MA 02115, USA.
Special examinations exist for many chronic diseases, which can diagnose the disease while it is asymptomatic, with no signs or symptoms. The earlier detection of disease may lead to more cures or longer survival. This possibility has led to public health programs which recommend populations to have periodic screening examinations for detecting specific chronic diseases, for example, cancer, diabetes, cardiovascular disease and so on.
View Article and Find Full Text PDFAm J Pathol
April 2004
Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, and the Dana Faber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Activin A, a dimeric glycoprotein that belongs to the transforming growth factor-beta superfamily, governs cellular differentiation in a wide variety of models and has been implicated in the regulation of angiogenesis. We examined the role of activin A and its downstream signaling pathway in a murine model of inflammatory corneal neovascularization induced by mechanical injury (debridement), and in vitro in corneal epithelial cells. Activin A expression increased steadily from day 2 until day 8 after mechanical debridement in vivo, paralleling vascular endothelial growth factor (VEGF) expression.
View Article and Find Full Text PDFCurr Opin Hematol
November 2003
Stem Cell Transplantation Program, Dana-Faber Cancer Institute, Division of Medical Oncology and Hematology, Brigham, MA, USA.
Purpose Of Review: Allogeneic transplantation can cure a number of hematologic malignancies; however, the cost in morbidity and mortality is high. Much of the toxicity is a direct consequence of the intensity of the conditioning regimen. It has gradually been recognized that the conditioning regimen is important but not critical for the success of transplantation, particularly in the less aggressive hematologic malignancies.
View Article and Find Full Text PDFNature
August 2003
Howard Hughes Medical Institute, Dana-Faber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Glycolysis and apoptosis are considered major but independent pathways that are critical for cell survival. The activity of BAD, a pro-apoptotic BCL-2 family member, is regulated by phosphorylation in response to growth/survival factors. Here we undertook a proteomic analysis to assess whether BAD might also participate in mitochondrial physiology.
View Article and Find Full Text PDFJ Nurs Adm
April 2003
Children's Hospital and Dana Faber Cancer Institute, Boston, MA 02115, USA.
Dev Biol
September 2002
Department of Adult Oncology and Cancer Biology, Dana-Faber Cancer Institute, Boston, MA 02115, USA.
Detailed study of the ectoderm and mesoderm has led to increasingly refined understanding of molecular mechanisms that operate early in development to generate cellular diversity. More recently, a number of powerful studies have begun to characterize the molecular determinants of the endoderm, a germ layer previously neglected in developmental biology. Work in diverse model systems has converged on an integrated transcriptional and signaling pathway that serves to establish the vertebrate endoderm.
View Article and Find Full Text PDFMethods Mol Biol
July 2000
Division of Molecular Genetics, Dana Faber Cancer Institute, Boston, MA, USA.
Cancer Res
April 1999
The Dana-Faber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA.
The two major hereditary breast cancer susceptibility genes, BRCA1 and BRCA2, are associated with early-onset breast and/or ovarian cancer and encode products that each interact with the product of the eukaryotic RecA homologue, hRad51. We have recently found that BRCA1 and BRCA2 coexist in a common biochemical complex. The two proteins also colocalize in subnuclear foci in somatic cells as well as on the axial elements of developing synaptonemal complexes in meiotic cells.
View Article and Find Full Text PDFJ Biol Chem
October 1998
Department of Cancer Immunology & AIDS, Dana-Faber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.
Hydrogen peroxide-inducible clone (Hic)-5 is induced during the senescent process in human fibroblasts, and the overexpression of Hic-5 induces a senescence-like phenotype. Structurally, Hic-5 and paxillin, a 68-kDa cytoskeletal protein, share homology such as the LD motifs in the N-terminal half and the LIM domains in the C-terminal half. Here we show that Hic-5 binds to focal adhesion kinase (FAK) by its N-terminal domain, and is localized to focal adhesions by its C-terminal LIM domains.
View Article and Find Full Text PDFClin Nucl Med
April 1996
Division of Nuclear Medicine, Dana Faber Cancer Institute, Boston, MA 02115, USA.
J Virol
October 1995
Division of Molecular Genetics, Dana-Faber Cancer Institute.
Among the five immediate-early regulatory proteins of herpes simplex virus (HSV) type 1, only ICP0 is capable of activating all kinetic classes of viral genes. Consistent with its broad transactivating activity, ICP0 plays a major role in enhancing the reactivation of HSV from latency both in vivo and in vitro. Although not essential for viral replication, ICP0 confers a significant growth advantage on the virus, especially at low multiplicities of infection.
View Article and Find Full Text PDFCancer Chemother Pharmacol
June 1995
Dana-Faber Cancer Institute, Boston, MA 02115, USA.
Antifolates have been shown to increase the DNA strand breaks produced by the topoisomerase inhibitor etoposide. PT523 is a potent new antifolate that cannot be polyglutamated. Human SCC-25 squamous carcinoma cells were exposed to methotrexate, trimetrexate or PT523 at a concentration of 5 microM for 24 h along with various concentrations of etoposide or novobiocin during the final 2 h.
View Article and Find Full Text PDFCancer Treat Res
September 1995
Division of Biostatistics, Dana Faber Cancer Institute, Boston, MA 02155, USA.
Eur J Immunol
October 1994
Division of Lymphocyte Biology, Dana Faber Cancer Institute, Boston, MA 02115.
There is an antigen presenting cell (APC) in the lymphoid organs capable of presenting exogenous antigen (Ag) with major histocompatibility complex (MHC) class I molecules. This study was initiated to isolate clones of these APC to definitively establish their phenotype and to further study their properties. Murine bone marrow macrophages (BM M psi) were immortalized by overexpression myc and raf oncogenes.
View Article and Find Full Text PDFStat Med
December 1994
Statistical Center, Dana-Faber Cancer Institute, Boston, MA 02115.
Leukemia
May 1994
Dana-Faber Cancer Institute, Boston, Massachusetts.
Steel factor (SF) synergizes with a variety of hemopoietins to support the growth and differentiation of human progenitor cells. The human factor-dependent cell line MO7 has been used as a model to study the interaction of SF with other growth factors such as GM-CSF, because both factors support the proliferation of this cell line and are synergistic in combination. Previous studies have shown that this effect is not readily explained by the synergistic activation of early, cytosolic signal transduction intermediates such as tyrosine kinases, Raf-1, MAP2 kinase, or phospholipase C gamma.
View Article and Find Full Text PDFJ Exp Med
April 1994
Division of Immunogenetics, Dana-Faber Cancer Institute, Boston, Massachusetts.
We demonstrated earlier that individuals homozygous for conserved major histocompatibility complex (MHC)-extended haplotypes have low natural killer (NK) activity as measured by cytolysis of the K562 tumor cell lines. In the present study, we investigated the segregation and MHC linkage of NK activity in families in which MHC haplotypes of human histocompatibility leukocyte antigens (HLA)-A, -C, and -B, complotype, and DR specificities are known. In two informative families, low activity was inherited as a recessive trait linked to the MHC.
View Article and Find Full Text PDFFEBS Lett
January 1994
Division of Tumor Immunology, Dana-Faber Cancer Institute, Boston, MA 02115.
Dysregulation of hematopoietic cellular differentiation contributes to leukemogenesis. Unfortunately, relatively little is known about how cell differentiation is regulated. Considering that heat shock proteins (hsp) and specifically the small hsps have been increasingly linked to growth regulation, we sought to determine whether the mammalian small hsp (hsp28) is a growth-regulatory candidate during hematopoietic cell differentiation.
View Article and Find Full Text PDFPharmazie
March 1992
Dana-Faber Cancer Institute, Boston, Massachusetts.
Nucleic Acids Res
December 1991
Division of Cellular and Molecular Biology, Dana-Faber Cancer Institute, Boston, MA.
Polyoma middle T antigen (MTAg) transforms cells by associating with and activating a variety of intracellular proteins, including src family members and a phosphatidylinositol-3 kinase. In order to assist in the study of the relative importance of the various associated biochemical activities for transformation by polyomavirus MTAg, a library of MTAg mutants was constructed. Chemically mutagenized MTAg DNA was purified from wild-type DNA by separation on denaturing gradient gels and placed into a recombinant retrovirus vector.
View Article and Find Full Text PDF